uploads/2018/02/Consumer-2-1.png

JNJ’s Consumer Products: OTC, Women’s Health, and Wound Care

By

Updated

OTC segment’s revenue trends

In 4Q17, Johnson & Johnson’s (JNJ) OTC (over-the-counter) segment reported revenues of $1.1 billion. This report indicates ~6.4% growth on a year-over-year (or YoY) basis and 10.0% growth quarter-over-quarter.

In 4Q17, in the US market and outside the US markets (international markets), JNJ’s OTC products generated revenues of $406.0 million and $699.0 million, respectively, compared to $418.0 million and $621.0 million in 4Q16.

In fiscal 2017, JNJ’s OTC products generated revenues of $4.1 billion, which reflected ~3.7% growth on a YoY basis. In 2017, in the US and international markets, JNJ’s OTC products reported revenues of $1.7 billion and $2.4 billion, respectively, which is ~2.4% and ~4.7% growth on YoY basis.

Article continues below advertisement

Women’s Health segment’s revenue trends

In 4Q17, JNJ’s Women’s Health segment generated revenues of $262.0 million, which is an ~1.0% decline on a YoY basis.

In fiscal 2017, JNJ’s Women’s Health segment generated revenues of $1.0 billion, which reflected an ~2.0% decline on a YoY basis. In the US market and international markets, the Women’s Health segment generated revenues of $12.0 million and $1.0 billion, respectively.

Wound Care segment’s revenue trends

In fiscal 2017, JNJ’s Wound Care segment generated revenues of $779.0 million, which reflected ~2.3% growth on a YoY basis. In 2017, in the US market and international markets, JNJ’s Wound Care segment generated revenues of $437.0 million and $342.0 million, respectively.

In 4Q17, JNJ’s Wound Care segment reported revenues of $180.0 million, which is ~2.3% growth on a YoY basis. In 4Q17, in the US market and international markets, the Wound Care segment reported revenues of $95.0 million and $85.0 million, respectively, compared to $100.0 million and $76.0 million in 4Q16.

Among Johnson & Johnson’s peers in the OTC drugs market, Teva Pharmaceuticals (TEVA), AstraZeneca (AZN), and Sanofi (SNY) reported 4Q17 revenues of $5.5 billion, $5.7 billion, and $10.2 billion, respectively.

Advertisement

More From Market Realist